Rates of throat-related cancers have risen sharply since the 1980s and HPV, from oral sex, is thought to be the cause.
More than 200,000 New Zealand females have received the vaccine since 2008.
Pharmac director of operations Sarah Fitt said the possible changes came after a request for proposals process.
"Access to vaccines is an important issue for New Zealanders, and we've received a lot of feedback about widening access to the varicella and HPV vaccines, including from our expert clinical advisers.
"Pharmac has worked constructively with suppliers to negotiate significant savings which provide opportunities for these important vaccines to be made available to more people."
Other changes to the currently listed vaccines including brand changes and a move to a 2-dose schedule for vaccination against rotavirus.
"We're very pleased to open consultation on proposals that would see an extra 100,000 people immunised against potentially serious illnesses."
Pharmac is seeking feedback on the proposals by June 17. Last week's Budget boosted
Pharmac's budget by $124 million over four years.
The Government said DHBs would also give an extra $11 million towards Pharmac's budget next year.